DLA Piper represents Parnell Pharmaceuticals in initial public offering
DLA Piper has advised Parnell Pharmaceuticals Holdings (PARN) in its initial public offering on NASDAQ. PARN, an Australian-based veterinary pharmaceutical company with US operations located in Kansas City, Kansas, focuses on developing, manufacturing and commercialising innovative animal health solutions. The company currently markets five products for companion animals and production animals in 14 countries and augments […]